Innovent and GenFleet reach deal for KRAS inhibitor; TCR2 receives FDA's ODD on gavo-cel
Amgen became the first company in May to crack an undruggable target and earn approval for a KRAS inhibitor. Now, Innovent is looking to follow in its footsteps.
Chinese pharma companies Innovent and GenFleet have entered into an exclusive licensing agreement for developing and commercializing GenFleet’s GFH925, the company’s lead KRAS G12C candidate in the China, Hong Kong, Macau and Taiwan markets.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
